^
    Back
    Association details:
    Biomarker:CCR4 overexpression
    Cancer:Lymphoma
    Drug:tivumecirnon (FLX475) (CCR4 receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    RAPT Therapeutics Press Release
    Title:

    RAPT THERAPEUTICS REPORTS POSITIVE INITIAL DATA FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF FLX475 IN MULTIPLE CANCER INDICATIONS

    Published date:
    11/16/2020
    Excerpt:
    Early data from the first two patients with EBV+ lymphoma treated with FLX475 monotherapy show significant target tumor reduction, including one patient (1/2) who achieved a durable complete metabolic response...